Cardiovascular Systems, Inc. (CSI) CSII, presented 30-day results
from its ORBIT II study of coronary artery disease in a late-breaking
presentation at the 2013 European Association of Percutaneous Cardiovascular
Interventions (EuroPCR) conference in Paris.
ORBIT II is evaluating the safety and effectiveness of the company's orbital
atherectomy technology in treating patients with severely calcified coronary
lesions. This is the first Investigational Device Exemption study in history
to evaluate this problematic subset of patients. CSI completed ORBIT II
enrollment of 443 patients at 49 U.S. medical centers in November 2012 and
submitted its Premarket Approval application to the FDA on March 15, 2013.
Dr. Jeffrey Chambers of Metropolitan Heart and Vascular Institute,
Minneapolis, highlighted new data showing that 92.8 percent of patients were
free from severe angiographic complications at 30 days. Additionally, core lab
assessed final procedure residual stenosis was 4.7 percent.
“Patients who suffer from severely calcified coronary lesions are one of the
toughest-to-treat populations, and 30-day ORBIT II results demonstrate that
CSI's orbital atherectomy technology may be a practical treatment option,”
said Dr. Chambers. “Patients with moderate-to-severe calcium are more likely
to experience major adverse coronary events (MACE), or even death. To have a
potential solution for this problem is exciting.”
Dr. Chambers also presented the following 30-day data:
Freedom From MACE (30 Day) 89.8% Procedural Success 89.1%
MI (CK-MB >3x ULN 9.7% Successful Stent 97.7%
Delivery
Non Q-wave 8.8%
Q-wave 0.9%
Target Vessel/Lesion 1.4% Less than 50 % residual 98.6%
Revascularization stenosis
TVR 0.7%
TLR 0.7%
Cardiac Death 0.2% In hospital MACE 9.5%
MI (CK-MB >3x ULN 9.3%
Non Q-wave 8.8%
Q-wave 0.9%
TVR 0.7%
Cardiac Death 0.2%
According to estimates, moderate-to-severe arterial calcium is present in
nearly 40 percent of patients undergoing a percutaneous coronary intervention.
Moderate-to-severe calcium contributes to poor outcomes and higher treatment
costs in coronary interventions when traditional therapies are used, including
a significantly higher occurrence of death and MACE.
David L. Martin, CSI president and chief executive officer, said: “Coronary
arterial calcium is a significantly underestimated problem in medicine today.
We are committed to providing physicians with viable treatment options for
this devastating disease and we are encouraged by the ORBIT II results, which
demonstrate that our orbital technology may provide a solution for these
difficult to treat patients.”
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in